Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency

20092,026 citationsJournal Articlebronze Open Access

Authors

Stefan D. Anker · Stavanger University Hospital

Josep Comín Colet · Stavanger University Hospital

Gerasimos Filippatos · Stavanger University Hospital

Ronnie Willenheimer · Lund University

Kenneth Dickstein · University of Bergen

Helmut Drexler · Medizinische Hochschule Hannover

Thomas F. Lüscher

Abstract

Treatment with intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency, with or without anemia, improves symptoms, functional capacity, and quality of life; the side-effect profile is acceptable. (ClinicalTrials.gov number, NCT00520780).

Topics & Keywords

Erythropoietin and Anemia Treatment Heart Failure Treatment and Management Iron Metabolism and Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 361, Issue 25, pp. 2436-2448

DOI: 10.1056/nejmoa0908355

Field-Weighted Citation Impact: 42.71